Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of that 100B market target a 1% market share = 100M and at 45% profit or 45M that's a EPS of .04 times 50+ P/E equals a potential share valuation of 2$ per share. Now obviously this scenario is hypothetical and very forward looking but it demonstrates how little market share we need to grow to that valuation.
Calculation factors:
1,136B share count.
Sector presently around a 50 P/E ratio.
Doesn't account for share reduction if applicable in future.
Biotechologies sector valued at 775B growing @7.4%
Omnihealth targets 100B of 775B biotech space
Omnihealth Inc subsidiaries
Agelock biotechnologies:
Market targets:
therapeutic applications: pain, alzheimer, diabetes, and anti-aging.
And
Entourage biotech.
I'm glad we've been able to dig so deep. I love the passion on this board so much. From both angles.
No kidding lol jerks
correct omnihealth, inc is not special and has the same requirements any other entity has. but they are using this period of alternative reporting wisely in that they are actively working on proprietary products this will add additional time before an audit is done this gives them additional time even after audit is beginning to get things done at and a greatly reduced cost.
The designation was given for multiple reasons most notably the non current reporting I.E. "audited financial statements".
The company has met all requirements to maintain trading on the OTCM.
Facts and circumstances may differ, however generally, OTC Markets Group will remove the Caveat Emptor designation once the company meets the qualifications for Pink Current Information
the alternative reporting standard allows Omni to temporarily withhold audited information this keeps costs down and helps management focus on the transition. into the pharmaceutical biotech space.
This does not negate an audit down the line but it does satisfy the OTCM requirements to stay trading.
seriously? they are filed OTCM alternative reporting standards.
I'f they would of filed a form 15 with a form 25 to follow it that's bad. Their are different avenues the form 15 can take.
LMFAO...
Form 15 with the 12h status allows them to keep trading while they fulfilled their 3 year filing requirement 2016,2017,2018. Annuels to achieve A non reporting status to be quiet while they transform and continue to keep trading
Good morning ladies and gentlemen.
www.agelockbiotech.com "can't wait to see what products they launch under this entity.
we now know of 2 un-announced entities. That are still technically under wraps.
Great DD can result in premium bargain entry pricing when timed with markets and at triple 5 fully reset chart and pending updates we have been blessed to be able to be able to quietly load.
$OMHE DD NEW DEVELOPEMENTS
company OTCM profile:
https://www.otcmarkets.com/stock/OMHE/profile
company has caveat emptor because it saught a quiet period as a pharmaceutical and to save $$ management was very smart and has proven theyre knowledgeable. entities now form in deleware not NVSOS to maintain their privacy and operations. imo..
2 previously PR'd target acquisitions found both of them yet to be announced
you got it boss, i look forward to reviewing my bogus claim DD packet with loads of snippets.
correct,
its important to note the switch from NVSOS filing to deleware this has afforded the company a level of privacy not available in the NVSOS system. deleware is one of the biggest filings locations globally comparable to tax haven caymen islands its the american variant. the building their filings are held at their is some 6,000+ companies registered if i recall correctly. their is a caymen building with 20,000 entities inside of it for tax purposes as an example.
also deleware is more reputable than NVSOS, imo.
site links
https://www.agelockbiotech.com/blog/
https://www.agelockbiotech.com/post/recipe-of-the-day
https://www.agelockbiotech.com/blog/categories/living-well
https://www.agelockbiotech.com/blog/categories/healthy-tips
https://www.agelockbiotech.com/post/how-dietitians-fuel-for-the-morning
MCIG high on smoke? with 75M shares held in $OMHE? not likely.
we have the researched fundamentals we have entry point technical's we now need fundamental filings to show legal fruition of our findings then when we learn about deals and revenues we can value the companies future fundamental potential and find a techincal valuation on our chart to know when ratios get to high for a over valuation.
rinse repeat.
anything FDA could yield P/E ratios 60x revenues as a pharmaceutical entity.
once those entities are made knowledgeable on the filings we will look for previously announced deals to fruition into legal values on the filings of their 10-q's and 10-k's.
i believe the transition took longer than planned and for reasons unknown at this time. but they have been working diligently and quietly behind the scenes.
i believe 2020 to be a big year for the company. time will tell.
incoming :)!! https://www.agelockbiotech.com/
400 W 41st Street Suite 506 Miami Beach, FL 33140
DRCBD.MD
lets goooooooooo!!!!!!!!!
what does the companies SIC CODE MEAN see here:
2834 Pharmaceutical Preparations
Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final consumption, such as ampoules, tablets, capsules, vials, ointments, medicinal powders, solutions, and suspensions. Products of this industry consist of two important lines, namely: (1) pharmaceutical preparations promoted primarily to the dental, medical, or veterinary professions, and (2) pharmaceutical preparations promoted primarily to the public.
Adrenal pharmaceutical preparations
Analgesics
Anesthetics, packaged
Antacids
Anthelmintics
Antibiotics, packaged
Antihistamine preparations
Antipyretics
Antiseptics, medicinal
Astringents, medicinal
Barbituric acid pharmaceutical preparations
Belladonna pharmaceutical preparations
Botanical extracts: powdered, pilular, solid, and fluid, except
Chlorination tablets and kits (water purification)
Cold remedies
Cough medicines
Cyclopropane for anesthetic use (U.S.P. par N.F.), packaged
Dermatological preparations
Dextrose and sodium chloride injection, mixed
Dextrose injection
Digitalis pharmaceutical preparations
Diuretics
Effervescent salts
Emulsifiers, fluorescent inspection
Emulsions, pharmaceutical
Fever remedies
Galenical preparations
Hormone preparations, except diagnostics
Insulin preparations
Intravenous solutions
Iodine, tincture of
Laxatives
Liniments
Lip balms
Lozenges, pharmaceutical
Medicines, capsuled or ampuled
Nitrofuran preparations
Ointments
Parenteral solutions
Penicillin preparations
Pharmaceuticals
Pills, pharmaceutical
Pituitary gland pharmaceutical preparations
Poultry and animal remedies
Powders, pharmaceutical
Procaine pharmaceutical preparations
Proprietary drug products
Remedies, human and animal
Sodium chloride solution for injection, U.S.P.
Sodium salicylate tablets
Solutions, pharmaceutical
Spirits, pharmaceutical
Suppositories
Syrups, pharmaceutical
Tablets, pharmaceutical
Thyroid preparations
Tinctures, pharmaceutical
Tranquilizers and mental drug preparations
Vermifuges
Veterinary pharmaceutical preparations
Vitamin preparations
Water decontamination or purification tablets
Water, sterile: for injections
Zinc ointment
]
OTCM shows address changed
https://www.otcmarkets.com/stock/OMHE/profile
previous:
Positive volume this week.
Those who've done the DD have resounding resilience to unproven claims against Omni. It shows in the positive posts day in day out.
It's indisputable that movement has been underway for some time.
it feels awesome to know Omni seeks to eliminate opioid pain options and persue options that are exciting and at the forefront of medical science that's not been available for far to long.
if Omni executes a pain cream formulation to treat pain and is executed through an FDA approved method it is arguably in a niche community of companies in that area of the pain market the FDA pain market. Pain management is a 100 billion dollar market in the USA.
Now, now. That's not àccurate.
My DD has uncovered movement that includes
DRCBD.MD
relivatrol.com
Paincream.md
Damian Forbes omnihealth, Inc partner.
Entourage biotech.
Your quick to diss-credit me and I'm no really ok with it.
Thus your statement is premature and innacurate. And does not speak for or on my behalf.
Shouldn't be relevant by then. if it is we both should not be investing lmfao
If we still going back and forth on here over the same issues and not making up on a Bahama cruise we are something else lmfao
Lol. Is anyone out their cause it's getting harder and harder to breath.
done with Vaca. Back at it let's go.
I think it is time to crank up the pressure on management. time for some activism.
Sending a letter to management.
no reply from management will result in cranking up the heat.
Lol the 1yr anniversary is here. Happy birthday unsubstantiated claim!
your suggesting the following then?
3 doctors with harvard, yale backgrounds would ruin everything they have worked for?
paul bought into a 26 employee scam?
all the information on the SEC filings are untruthful?
that you can prove malecon was sold?
that you can prove andrey lied to everyone.
that everything PR'd was a lie.
go ahead ill wait.
reputations hinge on the above...
i mean i could keep going with suggestions but i don't desire to feed into something without a ROT "return on time" i want facts and i submitted a lot of information and i am open to a negative dialogue so long as its not a one way road.
YW. fact based took 10 mins lol
is it? do you do your DD? or just? here look:
http://voyagemia.com/interview/meet-andrew-damian-forbes-author-wealth-wheel-ebook-founder/
Fishing is part of DUE diligence.
I can dismiss this finding once a filing of some kind is filed.
I like fishing
Not so fast to dissmiss their captain. Cause I'd like to see otherwise.
Here you go
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174962
No PR was issued.
Also see this recent finding
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150175434
Also this link on quiet periods is a great read.
https://westwicke.com/2014/06/commonly-asked-questions-about-quiet-periods/
omnihealth, Inc now registered in more reputable deleware
If I had to make a guess about the company talking I think 7 months we could hear something.
That puts us on par with annual shareholder letters. February 2020.
Time will tell. we don't know what lx has as far as operations. we can't value it until we know more, maybe lx retail changes its name.
the board is quiet, the price is sideways.
stock trades as a biotech otc. With filing s in Delaware now proving their actively working as a business.
I'm excited, lots of questions I've got about my research and some DOTS is like to connect.
But this ones on the hold and watch it list for me pending updates from management.
A nice read on biotech stocks. No particular entity is applicable however Omni is within the biotech sphere so it's applied and relevant here you are:
https://www.statnews.com/2019/07/31/why-biotech-companies-are-often-at-the-whim-of-things-they-cannot-control-in-one-chart/